PreludeDx Taps Veteran Operations Leader MiMi Reyes to Scale Breast Cancer Diagnostics Amid Surging Demand

LAGUNA HILLS, Calif. – January 22, 2026 – Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer, today announced a significant strategic appointment, naming diagnostics industry veteran MiMi Reyes as its new Senior Vice President of Operations. The move signals a pivotal moment for the company as it prepares to scale its infrastructure to meet rapidly growing demand for its existing tests and support the imminent launch of its next-generation AidaBreast test for invasive breast cancer.

Reyes, who brings over 25 years of executive experience in diagnostics and medical devices, will be responsible for overseeing and expanding all laboratory operations, including technology and automation. The appointment is seen as a critical step in fortifying the company’s operational backbone as it enters a new phase of growth.

"MiMi's operational leadership, deep understanding of regulated diagnostics, and proven ability to build and scale high-quality laboratory operations make her an exceptional addition to PreludeDx," said Dan Forche, President and CEO of PreludeDx. "Her experience will be instrumental as we strengthen our operations to support higher patient demand and the new launch of our AidaBreast invasive breast cancer test."

A Strategic Hire to Meet Surging Demand

The decision to bring in an executive of Reyes' caliber comes as PreludeDx experiences what it calls "accelerating demand" for its flagship product, DCISionRT. This test has become a cornerstone in the management of ductal carcinoma in situ (DCIS), or stage 0 breast cancer. By analyzing a patient's unique tumor biology, DCISionRT provides a personalized risk score, helping physicians and patients decide whether radiation therapy is truly necessary after surgery.

Recent clinical data has reinforced the test's value, showing its ability to safely de-escalate treatment for many women, even some with high-risk clinical features, by identifying those who have a low 10-year risk of recurrence without radiation. This ability to prevent overtreatment has driven its adoption by clinicians nationwide.

A significant commercial milestone was achieved on April 1, 2023, when the test received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS). This designation not only confirmed the test's clinical value and unique nature but also secured its reimbursement and access for a vast population of Medicare patients, further fueling its growth trajectory. The company’s $20 million funding round in 2022 was explicitly aimed at advancing this commercial expansion, and Reyes' appointment appears to be the next logical step in executing that plan.

A Pioneer with a Blueprint for Growth

MiMi Reyes is not new to the challenges of scaling high-stakes diagnostic operations. Her career is a testament to her ability to build and lead robust, compliant, and efficient laboratory systems. Before joining PreludeDx, she served on the Executive Management team at MDxHealth, where she was responsible for Global Operations, leading diagnostic programs in prostate, bladder, and urinary tract cancers.

Her impact there was foundational; she was hired in 2011 to establish the company's first U.S.-based CLIA-certified laboratory in Irvine, California, preparing the groundwork for the successful U.S. launch of its first prostate cancer assay in 2012. Her leadership was integral to scaling operations in a complex, global environment.

Perhaps most relevant to her new role is her history as an early pioneer at Agendia. There, she played a key part in supporting the launch of MammaPrint, one of the first and most recognized genomic tests for guiding chemotherapy decisions in early-stage breast cancer. This direct experience in the breast cancer diagnostics space provides her with invaluable insight into the market PreludeDx aims to lead.

Her expertise spans the full spectrum of regulatory compliance, including managing laboratories that adhere to the stringent standards of CAP, CLIA, FDA, and ISO. This deep regulatory knowledge is crucial for ensuring that as test volumes increase, quality and reliability remain uncompromised.

"I'm excited to join PreludeDx at an important time for the company," said Ms. Reyes. "PreludeDx has built a strong foundation in precision diagnostics, and I look forward to partnering across teams to further strengthen operations, innovation, and ensure the delivery of high-quality testing that positively impacts patients."

Paving the Way for AidaBreast

Beyond managing current growth, Reyes' primary mandate includes preparing the operational infrastructure for the launch of AidaBreast, PreludeDx's highly anticipated test for early-stage invasive breast cancer. This new test represents a significant expansion for the company, moving from its established niche in non-invasive DCIS to the much larger market of invasive disease.

AidaBreast is a novel multi-omic biosignature, meaning it analyzes a combination of RNA, protein expression, and spatial biology to create a comprehensive profile of a tumor. It is designed specifically for women with Stage I and IIa, HR+/HER2- breast cancer who have undergone breast-conserving surgery.

Its key differentiator in a crowded market is its purpose: AidaBreast is the first commercially developed test focused specifically on predicting both the 10-year risk of locoregional recurrence and a patient's individualized benefit from adjuvant radiation therapy. While competitors like Oncotype DX and MammaPrint have successfully guided chemotherapy decisions for years, the question of who benefits from radiation after lumpectomy has remained a significant clinical challenge. AidaBreast aims to fill that gap.

Results from the first independent validation study, presented in late 2025, were promising. The study, conducted at Royal Melbourne Hospital in Australia, confirmed that the test could effectively stratify women into risk groups and identify which patients in the elevated-risk category would derive a significant benefit from radiation, potentially sparing others from unnecessary treatment. This positions AidaBreast as a major advance in personalizing radiotherapy decisions, much as DCISionRT did for DCIS.

Navigating a Competitive and Evolving Market

The breast cancer diagnostics market is a multi-billion dollar industry, projected to grow substantially over the next decade. While dominated by imaging technologies for initial screening, the segment for predictive genomic tests is where the most intense innovation and competition are taking place. PreludeDx is positioning itself against established giants like Exact Sciences and its own former pioneers from Agendia.

By appointing MiMi Reyes, PreludeDx is sending a clear message to the market and its investors: it is ready to transition from a promising innovator to a major commercial player. Her proven ability to scale operations is the engine required to power the company's commercial ambitions for both DCISionRT and AidaBreast. Building out the capacity for high-volume, high-quality, and rapid-turnaround testing is essential to compete effectively and gain physician trust.

Ultimately, this strategic hire links directly back to the company's mission of improving patient outcomes through personalized medicine. As PreludeDx expands its reach, ensuring that every test is processed with the highest level of accuracy and efficiency is paramount. With Reyes at the operational helm, the company is fortifying its ability to deliver on the promise of its technology, ensuring that more patients can benefit from treatment decisions guided by their own unique biology.